A 2A receptor antagonism and dyskinesia in parkinson's disease

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Morelli, Micaela ^a,b   Blandini, Fabio ^c   Simola, Nicola ^a   Hauser, Robert A ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; APOMORPHINE; BIOLOGICAL MARKER; CAFFEINE; DOPAMINE; GLUTAMIC ACID; ISTRADEFYLLINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; PRELADENANT; TOZADENANT; VIPADENANT;

BASAL GANGLION; BIOCHEMISTRY; BRAIN BLOOD FLOW; BRAIN REGION; DENERVATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG INDICATION; DYSKINESIA; HUMAN; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW;

EID: 84863687148     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/489853     Document Type: Review

References (56)

1. Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A. E., Adler E. M., Reppert S. M., Molecular cloning of the rat A 2 adenosine receptor: selective co-expression with D 2 dopamine receptors in rat striatum Molecular Brain Research 1992 14 3 186 195
2. Schiffmann S. N., Libert F., Vassart G., Vanderhaeghen J. J., Distribution of adenosine A 2 receptor mRNA in the human brain Neuroscience Letters 1991 130 2 177 181
3. Canals M., Marcellino D., Fanelli F., Ciruela F., De Benedetti P., Goldberg S. R., Neve K., Fuxe K., Agnati L. F., Woods A. S., Ferré S., Lluis C., Bouvier M., Franco R., Adenosine A2A -dopamine D 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer Journal of Biological Chemistry 2003 278 47 46741 46749 (Pubitemid 37452253)
4. Fuxe K., Agnati L. F., Jacobsen K., Hillion J., Canals M., Torvinen M., Tinner-Staines B., Staines W., Rosin D., Terasmaa A., Popoli P., Leo G., Vergoni V., Lluis C., Ciruela F., Franco R., Ferré S., Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease Neurology 2003 61 11 S19 S23
5. Hillion J., Canals M., Torvinen M., Casad V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M. E., Mallol J., Canela E. I., Zoli M., Agnati L. F., Ibez C. F., Lluis C., Franco R., Ferré S., Fuxe K., Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D 2 receptors Journal of Biological Chemistry 2002 277 20 18091 18097 (Pubitemid 34967623)
6. Short J. L., Ledent C., Borrelli E., Drago J., Lawrence A. J., Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice Neuroscience 2006 139 2 661 670
7. Morelli M., Di Paolo T., Wardas J., Calon F., Xiao D., Schwarzschild M. A., Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications Progress in Neurobiology 2007 83 5 293 309 (Pubitemid 350102747)
8. Pinna A., Pontis S., Borsini F., Morelli M., Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease Synapse 2007 61 8 606 614 (Pubitemid 46934007)
9. Hauser R. A., Schwarzschild M. A., Adenosine A2A receptor antagonists for Parkinson's disease rationale, therapeutic potential and clinical experience Drugs and Aging 2005 22 6 471 482 (Pubitemid 41003061)
10. Adair T. H., Growth regulation of the vascular system: an emerging role for adenosine American Journal of Physiology 2005 289 2 R283 R296
11. Lukashev D., Ohta A., Apasov S., Chen J. F., Sitkovsky M., Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo Journal of Immunology 2004 173 1 21 24 (Pubitemid 38797321)
12. Calon F., Dridi M., Hornykiewicz O., Bédard P. J., Rajput A. H., Di Paolo T., Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias Brain 2004 127 5 1075 1084 (Pubitemid 38623043)
13. Pinna A., Corsi C., Carta A. R., Valentini V., Pedata F., Morelli M., Modification of adenosine extracellular levels and adenosine A2A receptor mRNA by dopamine denervation European Journal of Pharmacology 2002 446 1-3 75 82 (Pubitemid 34722559)
14. Tomiyama M., Kimura T., Maeda T., Tanaka H., Kannari K., Baba M. A., Upregulation of Striatal Adenosine A2A Receptor mRNA in 6-Hydroxydopamine- Lesioned Rats Intermittently Treated with L-DOPA Synapse 2004 52 3 218 222 (Pubitemid 38581671)
15. Brooks D. J., Papapetropoulos S., Vandenhende F., Tomic D., He P., Coppell A., O'Neill G., An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers Clinical Neuropharmacology 2010 33 2 55 60
16. Mishina M., Ishiwata K., Naganawa M., Kimura Y., Kitamura S., Suzuki M., Hashimoto M., Ishibashi K., Oda K., Sakata M., Hamamoto M., Kobayashi S., Katayama Y., Ishii K., Adenosine A2A receptors measured with [11C]TMSX pet in the striata of parkinson's disease patients PLoS ONE 2011 6 2
17. Pinna A., Fenu S., Morelli M., Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatment in 6-hydroxydopamine-lesioned rats Synapse 2001 39 3 233 238 (Pubitemid 32099678)
18. Henry B., Crossman A. R., Brotchie J. M., Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Experimental Neurology 1998 151 2 334 342 (Pubitemid 28285913)
19. Pinna A., Pontis S., Morelli M., Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment Behavioural Brain Research 2006 171 1 175 178 (Pubitemid 43728402)
20. Tronci E., Simola N., Borsini F., Schintu N., Frau L., Carminati P., Morelli M., Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats European Journal of Pharmacology 2007 566 13 94 102 (Pubitemid 46782796)
21. Lundblad M., Vaudano E., Cenci M. A., Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia Journal of Neurochemistry 2003 84 6 1398 1410 (Pubitemid 36343606)
22. Grondin R., Bédard P. J., Tahar A. H., Grégoire L., Mori A., Kase H., Antiparkinsonian effect of a new selective adenosine A(2A) receptor antagonist in MPTP-treated monkeys Neurology 1999 52 8 1673 1677 (Pubitemid 29220647)
23. Hodgson R. A., Bedard P. J., Varty G. B., Kazdoba T. M., Di Paolo T., Grzelak M. E., Pond A. J., HadjTahar A., Belanger N., Gregoire L., Dare A., Neustadt B. R., Stamford A. W., Hunter J. C., Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders Experimental Neurology 2010 225 2 384 390
24. Kanda T., Jackson M. J., Smith L. A., Pearce R. K. B., Nakamura J., Kase H., Kuwana Y., Jenner P., Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D 1 or D 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Experimental Neurology 2000 162 2 321 327 (Pubitemid 30217727)
25. Bibbiani F., Oh J. D., Petzer J. P., Castagnoli N., Chen J. F., Schwarzschild M. A., Chase T. N., A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease Experimental Neurology 2003 184 1 285 294 (Pubitemid 37444038)
26. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Sibley D. R., D 1 and D 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 1990 250 4986 1429 1432 (Pubitemid 120031867)
27. Carta A. R., Pinna A., Cauli O., Morelli M., Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats Synapse 2002 44 3 166 174 (Pubitemid 34303914)
28. Zeng B. Y., Pearce R. K. B., MacKenzie G. M., Jenner P., Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA European Journal of Neuroscience 2000 12 3 1096 1104 (Pubitemid 30168788)
29. Ferré S., Fredholm B. B., Morelli M., Popoli P., Fuxe K., Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia Trends in Neurosciences 1997 20 10 482 487 (Pubitemid 27421712)
30. Rosin D. L., Hettinger B. D., Lee A., Linden J., Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function Neurology 2003 61 11 S12 S18
31. Gardoni F., Ghiglieri V., Luca M. D., Calabresi P., Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease Progress in Brain Research 2010 183 C 169 182
32. Chase T. N., Bibbiani F., Bara-Jimenez W., Dimitrova T., Oh-Lee J. D., Translating A2A antagonist KW6002 from animal models to parkinsonian patients Neurology 2003 61 11 S107 S111
33. Wirkner K., Gerevich Z., Krause T., Gnther A., Kles L., Schneider D., Nrenberg W., Illes P., Adenosine A2A receptor-induced inhibition of NMDA and GABA A receptor-mediated synaptic currents in a subpopulation of rat striatal neurons Neuropharmacology 2004 46 7 994 1007 (Pubitemid 38471953)
34. Calabresi P., Galletti F., Saggese E., Ghiglieri V., Picconi B., Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits Parkinsonism and Related Disorders 2007 13 3 S259 S262
35. Kelley A. E., Andrzejewski M. E., Baldwin A. E., Hernandez P. J., Pratt W. E., Glutamate-mediated plasticity in corticostriatal networks: role in adaptive motor learning Annals of the New York Academy of Sciences 2003 1003 159 168 (Pubitemid 38083053)
36. Ferré S., Karcz-Kubicha M., Hope B. T., Popoli P., Burgueo J., Gutiérrez M. A., Casad V., Fuxe K., Goldberg S. R., Lluis C., Franco R., Ciruela F., Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11940 11945 (Pubitemid 34994503)
37. Kachroo A., Orlando L. R., Grandy D. K., Chen J. F., Young A. B., Schwarzschild M. A., Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice Journal of Neuroscience 2005 25 45 10414 10419 (Pubitemid 41628445)
38. Lopez S., Turle-Lorenzo N., Johnston T. H., Brotchie J. M., Schann S., Neuville P., Amalric M., Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats Neuropharmacology 2008 55 4 483 490
39. Johnston T. H., Fox S. H., McIldowie M. J., Piggott M. J., Brotchie J. M., Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease Journal of Pharmacology and Experimental Therapeutics 2010 333 3 865 873
40. Carriba P., Ortiz O., Patkar K., Justinova Z., Stroik J., Themann A., Mller C., Woods A. S., Hope B. T., Ciruela F., Casad V., Canela E. I., Lluis C., Goldberg S. R., Moratalla R., Franco R., Ferré S., Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids Neuropsychopharmacology 2007 32 11 2249 2259 (Pubitemid 47587686)
41. Ferré S., Llus C., Justinova Z., Quiroz C., Orru M., Navarro G., Canela E. I., Franco R., Goldberg S. R., Adenosine-cannabinoid receptor interactions. Implications for striatal function British Journal of Pharmacology 2010 160 3 443 453
42. ukasiewicz S., Basiak E., Faron-Grecka A., Polit A., Tworzydo M., Grecki A., Wasylewski Z., Dziedzicka-Wasylewska M., Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane Pharmacological Reports 2007 59 4 379 392
43. Ciruela F., Casad V., Rodrigues R. J., Lujn R., Burgueo J., Canals M., Borycz J., Rebola N., Goldberg S. R., Mallol J., Cortés A., Canela E. I., Lpez-Giménez J. F., Milligan G., Lluis C., Cunha R. A., Ferré S., Franco R., Presynaptic control of striatal glutamatergic neurotransmission by adenosine A 1-A2A receptor heteromers Journal of Neuroscience 2006 26 7 2080 2087
44. Popoli P., Frank C., Tebano M. T., Potenza R. L., Pintor A., Domenici M. R., Nazzicone V., Pzzola A., Reggio R., Modulation of glutamate release and excitotoxicity by adenosine A2A receptors Neurology 2003 61 11 S69 S71
45. Mishina M., Ishiwata K., Kimura Y., Naganawa M., Oda K., Kobayashi S., Katayama Y., Ishii K., Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET Synapse 2007 61 9 778 784 (Pubitemid 47122751)
46. Ramlackhansingh A. F., Bose S. K., Ahmed I., Turkheimer F. E., Pavese N., Brooks D. J., Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease Neurology 2011 76 21 1811 1816
47. Black K. J., Koller J. M., Campbell M. C., Gusnard D. A., Bandak S. I., Quantification of indirect pathway inhibition by the adenosine A2A antagonist SYN115 in Parkinson disease Journal of Neuroscience 2010 30 48 16284 16292
48. Varani K., Vincenzi F., Tosi A., Gessi S., Casetta I., Granieri G., Fazio P., Leung E., MacLennan S., Granieri E., Borea P. A., A2A adenosine receptor overexpression and functionality, as well as TNF- levels, correlate with motor symptoms in Parkinson's disease FASEB Journal 2010 24 2 587 598
49. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M. J., Mouradian M. M., Chase T. N., Adenosine A2A receptor antagonist treatment of Parkinson's disease Neurology 2003 61 3 293 296 (Pubitemid 36975954)
50. Hauser R. A., Hubble J. P., Truong D. D., Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD Neurology 2003 61 3 297 303 (Pubitemid 36975955)
51. LeWitt P. A., Guttman M., Tetrud J. W., Tuite P. J., Mori A., Chaikin P., Sussman N. M., Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Annals of Neurology 2008 63 3 295 302 (Pubitemid 351499859)
52. Stacy M., Silver D., Mendis T., Sutton J., Mori A., Chaikin P., Sussman N. M., A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease Neurology 2008 70 23 2233 2240
53. Hauser R. A., Shulman L. M., Trugman J. M., Roberts J. W., Mori A., Ballerini R., Sussman N. M., Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations Movement Disorders 2008 23 15 2177 2185
54. Mizuno Y., Hasegawa K., Kondo T., Kuno S., Yamamoto M., Sakou K., Shoji M., Abe T., Nomura H., Maeda T., Shintani S., Tamaoka A., Hirata K., Hishida R., Nakano I., Okamoto K., Asahina M., Shimura H., Hashida H., Mochizuki H., Mizusawa H., Hanajima R., Suzuki Y., Nakamura S., Yokochi M., Yokochi F., Takahashi H., Hashimoto T., Morita H., Miyajima H., Ohashi T., Atsumi T., Mizoguchi K., Hattori T., Sawada H., Tatsuoka Y., Matsumoto S., Fujimura H., Miwa H., Nakashima K., Yoshinaga J., Nomoto M., Yamada T., Uozumi T., Tanji H., Takeda A., Kawashima N., Ishigaki Y., Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study Movement Disorders 2010 25 10 1437 1443
55. Knebel W., Rao N., Uchimura T., Mori A., Fisher J., Gastonguay M. R., Chaikin P., Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with parkinson's disease Journal of Clinical Pharmacology 2011 51 1 40 52
56. Hauser R. A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., Huyck S., Wolski K., Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial The Lancet Neurology 2011 10 3 221 229